$ACT Recent Headlines Pharma love triangle is a win,

New Post Public Reply Private Reply Replies (0) Message Board

Oct 5, 2014 at 11:44 AM

$ACT Recent Headlines

Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:41 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:27 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:03 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang

Salix Seen as Target After Scrapping Tax Inversion Cosmo Purchase 12:07 p.m. Oct. 3, 2014 - TheStreet.com
Salix Cancels Tax Inversion, Opens Way For Buyers 10:11 a.m. Oct. 3, 2014 - Investors Business Daily
Wall Street Breakfast: 83M Accounts Exposed In JPMorgan Data Breach 6:31 a.m. Oct. 3, 2014 - Seeking Alpha
Bloomberg: Salix in talks with Actavis, Allergan deal fades 6:16 p.m. Oct. 2, 2014 - Seeking Alpha
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Actavis in Patent Infringement Lawsuit for Purdue's Butrans - Analyst Blog 5:20 p.m. Oct. 1, 2014 - Zacks.com
A Bizarre Pharma Love Triangle 4:00 p.m. Oct. 1, 2014 - Seeking Alpha
Ardelyx Bowel Drug Could Rival Actavis' Linzess 11:10 a.m. Oct. 1, 2014 - Investors Business Daily
Zogenix submits sNDA for abuse deterrent Zohydro 10:37 a.m. Oct. 1, 2014 - Seeking Alpha
Ireland Exporters Look To Thursday's ECB Policy Vote 5:24 p.m. Sept. 30, 2014 - Investors Business Daily
Top 10 Dow Dividend Stocks For October 9:39 a.m. Sept. 30, 2014 - InvestorPlace.com
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
Allergan Reiterates Opposition to Valeant Bid 8:41 a.m. Sept. 29, 2014 - The Wall Street Journal Interactive Edition
More concerns surface over Allergan's new bid 6:44 a.m. Sept. 28, 2014 - Seeking Alpha
T. Rowe Price Urges Allergan to Put Acquisitions to a Vote 10:54 p.m. Sept. 26, 2014 - The Wall Street Journal Interactive Edition
Meet 5 Top Stocks With Rising Earnings Estimates 7:02 a.m. Sept. 26, 2014 - Investors Business Daily
Trade-Ideas: Actavis (ACT) Is Today's New Lifetime High Stock 9:47 a.m. Sept. 25, 2014 - TheStreet.com
Dow Index Overseers Make It Official: U.S. Firms Only 8:43 p.m. Sept. 24, 2014 - The Wall Street Journal Interactive Edition
Facebook, Three Other Leaders In Striking Distance 5:08 p.m. Sept. 24, 2014 - Investors Business Daily

Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 10:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver 9:39 a.m. Sept. 24, 2014 - PR Newswire - PRF
Twenty Employers to Attend Annual Life Science Hiring Event Next Week 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension 5:10 p.m. Sept. 9, 2014 - PR Newswire - PRF
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Sept. 9, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Breach at Lumara Bio: Privacy Lawsuits Loom

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Pencil Reinvention Aims to Reduce Classroom Waste

Sharpen Those Ideas: Reinventing the Humble Pencil Every classroom has 'em: pencils chewed up faster than a kid chomping through bubblegum. This ain't new. But dig this—a Chicago teacher's coming in hot with a tweak to extend pencil life. How? By addressing the ol' crumbly eraser issue. You know, the kind that vanishes into thin air right when you need it most. So,...

VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

2026 Global Ocean Forum Unveils Key Marine Strategies

Riding the Waves in Qingdao It ain't every day that a talk-fest dedicated to oceans gets my attention, but when the Global Ocean Development Forum plants its flag in Qingdao, even I sit up. We're talking about some real fireworks in the marine economy sector with this gig's '1+1+4+8' framework. Now, before you scratch your head on the bingo numbers—it's the opening...

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

Hyundai and Texas Children's Boost Child Safety in Houston

A Meaningful Partnership for Safer Houston Roads There's a good feeling about corporations genuinely pitching in for community welfare, and Hyundai teaming up with Texas Children's Hospital to boost child passenger safety around Houston is exactly that. Pairing philanthropy with safety is more than just a business move—it's a testament to human decency. With a $25,000...

ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

MGM China Hits Record Highs Amid Market Challenges

Highs Amid Headwinds: MGM China's Standout Quarter Rolling into one's portfolio, MGM China isn't just coasting along—it's smashing some records, despite fierce headwinds. It's not all smooth sailing in Macau's gaming scene, but MGM China has hammered out its third-quarter results with gusto, setting new records for revenue and adjusted EBITDA. These folks aren't just...

Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...

NEO Battery's Quarter: Converting Leads to Contracts

NEO Battery's Bold Moves A glance at NEO Battery Materials Ltd.'s latest update feels like reading the playbook of a team stepping it up a notch. They're pushing those silicon-enhanced wonders into new territories—and doing so with one eye on expansion and the other on severe demand spikes from high-stakes sectors. From Leads to Customers No one's gonna raise eyebrows...